THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
We are excited to share that SeptiCyte® RAPID has been featured in the publication “The Diagnostic Utility of Host RNA Biosignatures in Adult Patients With Sepsis: A Systematic Review and Meta-Analysis” by Wolters Kluwer Health, Inc., on behalf of the Society of Critical Care Medicine.
The article emphasises the critical challenge in clinical diagnostics: differentiating sepsis from Systemic Inflammatory Response Syndrome (SIRS). This is precisely where SeptiCyte RAPID excels.
Key Highlights:
- The publication is a comprehensive meta-analysis conducted by esteemed research teams from Singapore and Oxford, UK.
- Transcriptomics emerges as a promising method for accurately diagnosing sepsis in adults, showing strong discriminatory power against both healthy individuals and those with SIRS.
- Transcriptomic signatures outperform traditional markers like CRP and PCT in sepsis diagnosis.
- SeptiCyte RAPID demonstrated excellent discriminatory ability in distinguishing sepsis from postoperative patient controls (AUC, 0.89) and showed excellent performance when differentiating sepsis from SIRS patients (AUC ranging from 0.77 to 0.95).
- This recognition underscores the clinical value of SeptiCyte RAPID in improving sepsis diagnosis and patient outcomes.
Read the journal article below.
*SeptiCyte RAPID is available for IVD use in Australia and New Zealand.
